<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408393</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2014-07</org_study_id>
    <nct_id>NCT02408393</nct_id>
  </id_info>
  <brief_title>MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery</brief_title>
  <acronym>MIRs03</acronym>
  <official_title>MIRs03: A Double-blind Randomized Trial of Paravertebral Block With Ropivacaine Before Breast Cancer Surgery: Effects on Chronic Postoperative Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the effect of paravertebral block (PVB) with Ropivacaine or placebo on the incidence
      of chronic pain 3 months after breast cancer surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before anesthesia, the second or third intercostal space is located. After an aspiration,
      0.35 mL/kg of solution (ropivacaine 7.5 mg/mL or saline, maximum 30 mL) are injected into the
      paravertebral space. After 30 minutes, spread of PVB is evaluated by cold test on skin. Then,
      general anesthesia is induced.

      Evaluation of the frequency of chronic pain at 3, 6 and 12 months by the Brief Pain Inventory
      (BPI) questionnaire and Neuropathic Pain Diagnostic (DN4) and Anxiety and depression
      evaluation by the Hospital Anxiety and Depression questionnaire (HAD) will be done.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 27, 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare chronic pain 3 months after breast surgery in each arm</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of patients who reported chronic pain 3 months after breast surgery in each arm evaluated by the Brief Pain Inventory, French version. Chronic pain is defined by the item 5 of BPI (upper or equal to 3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the extend of dermatomes blocked</measure>
    <time_frame>one year after surgery</time_frame>
    <description>The extent of dermatomes blocked as measured by clinical examination to determine area where temperature perception change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure acute postoperative pain (Visual Analog Scale (VAS)</measure>
    <time_frame>48 postoperative hours</time_frame>
    <description>Patient satisfaction on Visual Analog Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine analgesic consumption</measure>
    <time_frame>48 postoperative hours</time_frame>
    <description>consumption during the first 48 postoperative hours: morphine paracetamol and ketoprofen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To examine incidence of nausea and vomiting</measure>
    <time_frame>48 postoperative hours</time_frame>
    <description>Common Toxicity Criteria for Adverse Effects (CTCAE) V4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize chronic pain (Neuropathic Pain Diagnostic DN4 Questionnaire)</measure>
    <time_frame>3 months</time_frame>
    <description>Neuropathic Pain Diagnostic DN4 Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the frequency of chronic pain (BPI questionnaire and Neuropathic Pain Diagnostic (DN4)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>BPI questionnaire and Neuropathic Pain Diagnostic (DN4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare presence of lymphedema</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Clinical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate anxiety and depression evaluation (Hospital Anxiety and Depression questionnaire (HAD)</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Hospital Anxiety and Depression questionnaire (HAD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate complications of paravertebral block (CTCAE V4.03)</measure>
    <time_frame>12 months</time_frame>
    <description>CTCAE V4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the number of patients reporting pain at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical examination to confirm the results of Visual analog scale, pain scores BPI and DN4</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">380</enrollment>
  <condition>Malignant Neoplasm of Breast</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline (30 mL maximum)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ropivacaine 7.5 mg/mL (0.35 mL/kg of solution)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NA Cl 0.9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Naropeine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women with non-metastatic invasive breast carcinoma or breast carcinoma in situ
             treated by:

               -  either breast-conserving surgery with axillary lymph node dissection

               -  either radical surgery with or without axillary lymph node dissection.

          2. 18 years ≤ Age ≥ 85 years.

          3. ASA class 1, 2 or 3.

          4. No analgesic treatment for 2 days (no pre-existing chronic pain)

          5. If a biological control has been requested recently or deemed necessary by the
             Investigator, then it should be satisfactory : Adequate hematologic and hemostasis:
             neutrophil count (ANC) &gt; 1500/mm3, haemoglobin &gt; 9 g/dl and platelets &gt; 75 000/mm3,
             prothrombin time &gt; 70%, activated partial thromboplastin time &lt; 1.5 X Upper Limit of
             Normal (ULN)

          6. Life expectancy ≥ 2 years.

          7. Signed informed consent form.

          8. Patient able to meet the self-assessments questionnaires (sufficient understanding
             assessments, proficiency in French)

          9. Patient affiliated with a health insurance scheme (beneficiary or legal)

        There is no prohibition for people to take part simultaneously in another search and there
        is no exclusion cause at the end of the research period.

        Exclusion Criteria:

          1. Ongoing neoplasm or history of malignancy other than breast cancer with the exception
             of: basal cell carcinoma, cervical carcinoma in situ, other treated cancer that has
             not relapsed during the 5 years preceding inclusion in the trial.

          2. Bilateral breast carcinoma at the inclusion

          3. Male subjects.

          4. Metastatic breast carcinoma at diagnosis (M1).

          5. Severe heart, liver and respiratory failure (ASA 4)

          6. Allergy to local anesthetics and morphine.

          7. Use of analgesics during the 48 hours preceding the surgical procedure.

          8. History of breast surgery with painful sequelae

          9. Major deformation of the spine

         10. Puncture site infection

         11. History of substance abuse.

         12. Pregnant or lactating women, or women of childbearing potential without effective
             contraception

         13. Subjects deprived of their liberty or under guardianship (including temporary
             guardianship).

         14. Subjects unable to comply with medical follow-up of the trial for geographical, social
             or psychological reasons.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre FUMOLEAU, PHD</last_name>
    <role>Study Director</role>
    <affiliation>drci.promotion@curie.fr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Jean PERRIN</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine LACASSAGNE</name>
      <address>
        <city>Nice</city>
        <zip>06189 NICE Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSTITUT CURIE - Site Paris</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie site Saint-Cloud</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Cohen SP, Raja SN. Prevention of chronic postsurgical pain: the ongoing search for the holy grail of anesthesiology. Anesthesiology. 2013 Feb;118(2):241-3. doi: 10.1097/ALN.0b013e31827d4129.</citation>
    <PMID>23340346</PMID>
  </results_reference>
  <results_reference>
    <citation>Albi-Feldzer A, Mouret-Fourme E E, Hamouda S, Motamed C, Dubois PY, Jouanneau L, Jayr C. A double-blind randomized trial of wound and intercostal space infiltration with ropivacaine during breast cancer surgery: effects on chronic postoperative pain. Anesthesiology. 2013 Feb;118(2):318-26. doi: 10.1097/ALN.0b013e31827d88d8.</citation>
    <PMID>23340351</PMID>
  </results_reference>
  <results_reference>
    <citation>Gärtner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009 Nov 11;302(18):1985-92. doi: 10.1001/jama.2009.1568. Erratum in: JAMA. 2012 Nov 21;308(19):1973.</citation>
    <PMID>19903919</PMID>
  </results_reference>
  <results_reference>
    <citation>Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006 May 13;367(9522):1618-25. Review.</citation>
    <PMID>16698416</PMID>
  </results_reference>
  <results_reference>
    <citation>Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology. 2000 Oct;93(4):1123-33. Review.</citation>
    <PMID>11020770</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgery</keyword>
  <keyword>Paravertebral block</keyword>
  <keyword>Chronic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

